VCYT: the cash flow

MyFinsight

Cash Flow Overview

Change in Cash
-$99,433K
Free Cash flow
$32,253K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Stock-based compensation
Allocation of facilities and it ...
Depreciation and amortization
Others
Negative Cash Flow Breakdown
Purchase of short-term investmen...
Compensation expense
Compensation expense
Others

Cash Flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total revenue	139,071	140,636	376,509	NaN
Laboratory supplies and reagents expense	12,314	14,150	43,134	NaN
Sample collection expense	3,288	3,038	9,398	NaN
Compensation expense	9,804	6,705	17,906	NaN
Other cost	4,937	5,638	14,017	NaN
Allocation of facilities and it expenses	2,963	3,587	9,989	NaN
Cost of revenue-Testing	33,306	33,118	94,444	NaN
Product costs	1,401	1,923	1,864	NaN
License fees and royalties	313	318	888	NaN
Other cost	174	368	2,980	NaN
Allocation of facilities and it expenses	3	12	454	NaN
Cost of revenue-Product	1,891	2,621	6,186	NaN
Compensation expense	0	2	3,318	NaN
Other cost	8	215	3,118	NaN
Allocation of facilities and it expenses	0	0	925	NaN
Cost of revenue-Biopharmaceutical And Other	8	217	7,361	NaN
Intangible asset amortization - cost of revenue	2,707	2,707	7,959	NaN
Gross profit	101,159	101,973	260,559	NaN
Compensation expense	15,547	9,944	27,840	NaN
Direct expense	4,198	5,650	10,946	NaN
Other research and development expenses	5,460	3,214	5,278	NaN
Allocation of facilities and it expenses	1,893	2,041	5,901	NaN
Total research and development	27,098	20,849	49,965	NaN
Compensation expense	19,972	16,995	52,214	NaN
Direct expense	1,455	1,999	3,564	NaN
Other selling and marketing expenses	4,561	4,063	10,880	NaN
Allocation of facilities and it expenses	1,168	2,883	7,567	NaN
Total selling and marketing	27,156	25,940	74,225	NaN
Compensation expense	16,236	20,788	62,121	NaN
Other general and administrative expenses	13,471	5,102	56,132	NaN
Allocation of facilities and it expenses	-6,027	-8,523	-24,836	NaN
Total general and administrative	23,680	17,367	93,417	NaN
Impairment of assets	NaN	0	20,505	NaN
Intangible asset amortization - operating expenses-Intangible Asset Amortization	579	622	1,865	NaN
Other income, net	7,328	3,439	6,985	NaN
Income tax provision	1,267	-515	2,363	NaN
Net income	28,707	41,149	19,137	6,067
Depreciation and amortization	5,430	5,298	5,266	10,851
Loss on disposal of property, plant and equipment	-366	0	0	-15
Stock-based compensation	12,761	10,901	10,757	21,943
Deferred income taxes	-10	-568	-87	74
Noncash lease expense	732	702	689	1,600
Revaluation of acquisition-related contingent consideration	-350	-12,582	166	-2,879
Impairment loss	NaN	0	0	20,505
Non-cash loss on deconsolidation of subsidiary	NaN	-2,845	-3,863	NaN
Effect of foreign currency on operations	80	-11	-1,205	5,050
Supplies and inventory	NaN	219	-221	2,863
Amortization of discount on short-term investments	614	651	2,619	NaN
Accounts receivable	5,567	-3,150	-425	4,283
Supplies	870	NaN	NaN	NaN
Prepaid expenses and other current assets	1,306	-4,362	956	5,460
Other assets	132	-194	-1,720	1,389
Operating lease liabilities	-319	-799	-495	-1,186
Accounts payable	2,587	-492	-3,660	3,113
Accrued liabilities and deferred revenue	-6,120	-718	9,125	-2,091
Net cash provided by operating activities	35,215	52,583	44,757	38,967
Proceeds from sale of short-term investments	NaN	0	NaN	NaN
Proceeds from maturity of short-term investments	NaN	51,195	51,055	51,061
Loss on deconsolidation of subsidiary - cash	NaN	2,845	NaN	NaN
Acquisition of c2i, net of cash acquired	NaN	0	0	0
Purchase of short-term investments	124,999	50,000	0	99,998
Purchases of property, plant and equipment	2,962	3,780	2,792	3,105
Net cash used in investing activities	-127,961	-5,430	48,263	-52,042
Payment of contingent consideration for acquisition	NaN	0	NaN	NaN
Payment of taxes on vested restricted stock units	9,364	3,659	2,814	11,831
Proceeds from the exercise of common stock options and employee stock purchases	2,735	3,510	5,791	4,781
Net cash used in financing activities	-6,629	-149	2,977	-7,050
Decrease in cash, cash equivalents and restricted cash	-99,375	47,004	95,997	-20,125
Effect of foreign currency on cash, cash equivalents and restricted cash	-58	12	60	647
Net decrease in cash, cash equivalents and restricted cash	-99,433	47,016	96,057	-19,478
Cash, cash equivalents and restricted cash at beginning of period	364,226	317,210	240,631	NaN
Cash, cash equivalents and restricted cash at end of period	264,793	364,226	317,210	NaN

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

MyFinsight

Cash Flow Overview

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Cash Flow Overview

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow